Job Title: Events Manager Department: Development The Lymphoma Research Foundation (LRF) is the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. The Foundation’s mission is to eradicate lymphoma and serve those touched by this disease. LRF has funded...
The mission of the Advanced Practitioner Society for Hematology/Oncology (APSHO) is to improve the quality of care for patients with cancer by supporting critical issues in educational, clinical, and professional development for advanced practitioners in hematology and oncology. APSHO is excited to welcome two new members to the Board of Directors—Carolyn Grande, CRNP, AOCNP®,...
Medical journals are facing an onslaught of papers on COVID-19, but some must be interpreted with caution, say the editors of the Journal of Clinical Oncology. Medscape Medical News
Researcher Spotlight: Boyu Hu, MD University of Utah/Huntsman Cancer Institute Gene mutations and chromosomal alterations found in relapsed/refractory chronic lymphocytic leukemia (CLL) makes the disease more resistant to currently approved therapies and prone to earlier relapses. While these gene changes are advantageous to leukemia’s growth and proliferation, they also create new dependencies in leukemia that can be...
The debate over describing low-risk lesions in a way that avoids the word "cancer" has been rolling on for a while, ever since the National Cancer Institute proposed the idea in 2013. Now, a study suggests that the name given to these low-risk lesions has a substantial impact on the way in which patients view...
BARCELONA, Spain — The immune checkpoint inhibitor atezolizumab (Tecentriq, Genentech) is a safe, late-line treatment for patients with advanced urinary tract carcinomas who have significant comorbidities and whose therapeutic options are limited. However, efficacy is a little less clear. These were the conclusions from the postmarketing single-arm phase 3b SAUL trial, presented here in a...
The standard approach to treatment of breast implant–associated anaplastic large-cell lymphoma (BIA-ALCL) is complete oncologic resection, as per the 2019 National Comprehensive Cancer Network (NCCN) consensus guidelines. Results from a prospective study of 26 consecutive patients with confirmed BIA-ALCL between 2013 and 2018 show that en bloc surgical resection and explantation was curative in 100%...
Alarm has been raised over the occurrence of severe immune-related adverse events (irAEs), which required hospitalizations, in some patients with advanced lung cancer who had been treated with immunotherapy with checkpoint inhibitors followed by osimertinib (Tagrisso, AstraZeneca). Osimertinib is one of the newest in a class of tyrosine kinase inhibitors (TKIs) that target the epidermal...
NEW YORK (Reuters Health) - A semiautomated fact-checking tool, the Seek & Blastn tool, has found numerous errors in nucleotide-sequence reagents in biomedical research publications, researchers report. These reagents are short DNA or RNA sequences used in laboratory techniques such as gene knockdown or polymerase chain reaction. "I was surprised by the sheer number of incorrect...
Time Management Tips
27.5 ° C